Thus, this fixed-dose combination trial laid the foundation for dual inhibition apart from anti-CTLA4/anti-PD-1 pathways for clinical use and was recently FDA approved for patients with unresectable or metastatic melanoma (220). Here, PDCD1 is linked to metastatic melanoma.